PRE Prenetics Global Limited
$16.33
Prenetics Global Limited Q4 F2026 Earnings Call Transcript
AI Conference Call Analysis
Sign in or subscribe to read.Shannon Devine
Host
I can start, are we ready?
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Yes, go ahead, Shannon.
Shannon Devine
Host
Good morning, everyone, and welcome to Prenetics Third Quarter 2026 Earnings Livestream. I'm Shannon Devine, and I'll be your host today. Joining us this morning are Danny Young, Chief Executive Officer of Prenetics and co-founder of IME, and Brian Rosin, Chief Financial Officer of IME. Before we begin, please note that today's presentation contains forward-looking statements, including guidance. These statements involve risks and uncertainties, and actual results may differ materially. Please refer to the company's filings with the SEC. The full Q3 2026 shareholder letter and this investor presentation were published this morning and are available at irprunetics.com. Before we hear from Danny, let's watch a short 90-second video on what Prunetics and IME have achieved over the past 22 months.
David Beckham
Co-founder, IM8
genetics is the parent company of ima you know we created this supplement nutrition simple i make just covers everything in one sachet what are you willing to do to be the best you should get ima because it's got 92 ingredients that's your secret ima that's my secret ima you know you don't have to take 15 or 18 tablet every single morning it's just easy and it's so good for you and the longevity of your life
Giannis Antetokounmpo
IM8 Ambassador
Since the moment I took IOM8, man, I've been feeling incredible. IOM8 gives me that immunity and strength that I can wake up every morning and feel good and perform well.
Lily Collins
IM8 Ambassador
And I think for me, not only has my doctor recommended it to me, I know IOM8's done so much scientific research, and so that makes me feel like I'm in really safe hands with IOM8.
Aryna Sabalenka
IM8 Ambassador
It's an amazing product. It's really working. That's why I choose IOM8.
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
So with this $1 billion growth financing, we're able to test so much more, go into more channels, test new creatives, test new offline activations, partnerships.
Unknown promotional narrator
Video narrator
The best choose the best.
Shannon Devine
Host
I will now turn the call over to Danny Young, Chief Executive Officer of Prenetics. Danny?
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Great, thank you, Shannon. Good morning, everyone. Thank you, everyone, for joining us. I'm Danny Young, co-founder and CEO of Prenetics. Joining me is also Brian Rosin, our CFO designate. Brian will succeed Stephen Lowe as CFO on December 31st. Since joining IM8 in May, he has helped secure our $1 billion growth financing commitment from General Catalyst, set up our finance leadership in the U.S., meeting with hundreds of investors, and speaking to many new research analysts. I also want to thank Stephen for his eight years at Prenetics. Stephen, thank you for your dedication and partnership. I'm glad you will continue with us as a senior advisor. So let's get started, everyone. Again, thank you guys for joining. Now to the quarter, let's get to slide four. Let me start with the promise we made last quarter. We said adjusted free cash flow would turn positive in Q3. It did, at $4.1 million, $27.5 million of cash used in operations, more than offset by $31.6 million of net funding from General Catalyst. We said revenue will be between $63 and $64 million. We finished right at the top of that range. Today, we are reaffirming two numbers, our full year revenue of $220 to $230 million for full year 26. And I made revenue of more than $400 million for next year. and one number we set in August we have chosen to move. We now expect a second half adjusted EBITDA loss of 30 to 35 million dollars against the 8 to 12 million we previously provided. We realize this is a very large change and it's also a deliberate choice given the returns we are seeing. Our cash growing, the general cash financing, 70% of our marketing, new products on the way, and how early we are in this category. We are investing more and I will explain why in a few minutes. As mentioned, total revenue was $64.1 million. IMA contributed $62.9 million up almost 40% from Q2. We did that while bringing down our cost of acquiring a customer for the second quarter in a row. IM8 revenue has now grown for six consecutive quarters. September was our strongest month ever at $23.7 million of revenue, equivalent to an annualized revenue run rate of $284 million. Next slide. Yeah, those are the headline results. What matters more is what sits underneath them, and there's one number I will keep coming back to. So thus far, for every dollar we've invested in acquiring customers through the first six quarters of this year, those customers have now returned $1.68. That's gross profit. It's what's left after we make and ship the product. It's actually measured the same way General Catalyst measured it and on a more conservative margin than we actually earn. And keep in mind when General Catalyst made that commitment back in July, that dollar was roughly $1.44. So it continues to compound on a monthly basis. And then the key metric also is like, hey, where does that number go off to, right? And how does it evolve over time? So our early customers now show us this. Next slide. So as you can see, this is actually taking our earliest cohorts. And again, this is a big part of the reason why we're investing more into the business, because as you can see here, our first full quarter of business, which was in Q1 of 2005, where we had 27,000 customers that we acquired in last year. And now with this cohort, this cohort has now returned to us $4.10 of gross profit for every dollar that it cost us to acquire them. and we did this in under two years so a lot of you guys know you know being in the DDC subscription base the one key metric that is a gold standard is a if we can hit it this is going to be a solid business that metric is having a three to one LTV on CAC ratio based upon gross profit and we've been able to hit down our first cohorts and as you can see on the next two cohorts which is 91,000 customers that we acquired in the second and third quarters of last year is roughly about 2.7 to 1 right now and based upon the current pace we expect to get there in early 2027. One thing to keep in mind here though, these early customers cost us less to acquire, roughly about $104 each against currently $285. But today's customers, they actually spend far more on a first order, approximately $207 versus $113, and they are earning back what they cost us in about six months. Our bar for these cohorts is still the same three to one and typically this three to one benchmark is roughly within 36 months and we've been able to show it now for approximately three cohorts. We're going to do this in approximately less than two years. Next slide. And with those returns in mind, I'm just going to answer the question I expect many of you will have for myself and Brian. We delivered the revenue guide. Why is the loss larger than the range that we gave in August? As mentioned, we now expect a second half adjusted EBITDA loss of approximately $30 to $35 million. In August, we set $8 to $12 million. So right now, we are choosing to invest in growth due to the weight of the evidence we have on hand. and Eric Corder is more evidence of that. And I will provide this to you in five different parts. The first part, as you have just seen, again, more than 4X on our earliest customers, close to three on the next 91,000 and about six months to earn back what a customer cost us today. Second reason, this past quarter, we spent a record amount and brought in our largest group of new customers ever. September alone brought in more than 52,000 new customers, and 4 in 10 of them paid for three months up front. We pressed the hardest in September, which cost us more per customer than July did. Even so, our average cost for the quarter fell for the second straight time. to approximately $285 in terms of customer acquisition costs. The third reason, this quarter we grew 38% and our cash grew too. So we ended September with $111.5 million of cash and investments up from $109.4 million June in a quarter of record spending. That is because this was the first full quarter of our $1 billion commitment from General Catalyst and it worked as designed. They financed 70% of what we spent to acquire customers and are repaid from a cap share of what those same customers bring in. That leaves our capital for new products, three clinical trials, and for a lot of brand marketing. and four, what is coming in 27. So every return I just showed you was earned on our core products alone, which is basically two products. Hydration arrives in the first quarter of next year. And since August, we have signed Care Bears by IM8. Every customer we bring in now is someone we can afford, that we can offer a second and third product to at no further acquisition costs. And number five, the opportunity. So I mean, it's quite crazy to think even after extraordinary growth in the past 22 months, we still only hold a 0.14% of a $200 billion category, which quite frankly doesn't have a dominant leader. However, this is not an open-ended commitment to spend. We will keep investing at this pace for as long as we see these returns hold up. The two numbers that govern it and how we judge it by a quarterly basis is what it costs us to acquire a customer and the gross profit each group of these customers returns to us. If either of these turns against us, we will slow down and you will hear it from us first. But you put those five together, an expensive mistake would actually be to invest less. And we are doing it from a strength. The business we have already built earned $30.6 million this past quarter before acquisition marketing and brand partner costs. If we stopped acquiring new customers tomorrow, the customers we already have today will already make the company profitable on an adjusted EBITDA basis. So everything I've shown you so far comes from our own data. And as we showed last quarter, we actually got independent credit card data from Indigore. And you don't have to take our word for it. Now we can test this through an independent lens. So keep in mind, this is observed credit card activity in the US only with partial coverage of our own store rather than our reported revenue. So I will start with retention. because in the subscription business, it decides everything. So we've now only been in business for 22 months, but you can see now after 22 months, 11% of IME customers are still buying from us. That compares with 8.7% for Dorne, 8.5% for AG1, and 7.4% for Grunz. The same panel shows how fast we're growing. Next slide. In the first nine months of 2026, the IMH sales in the panel grew 348% year over year. And our share of these four brands went from 1% in January last year to 16% in December. We have the full investor deck as well as the full slides in the shareholder letter for everyone to read. And we also see the same loyalty inside our business. About 59% of customer billings this quarter came from repeat orders. Quarterly plans were about 61% of September billings. And we ended September with roughly 160,000 active subscriptions. So while we're saying that, is that a customer stay? We have one of the best retention cohorts in the category. And how do we keep reaching new ones? Next slide. And our partners are a big part of the answer. As everyone knows, David Beckham co-founded IM8. The people alongside us include Yanis, Irina Sabalenka, Ali Behrman, Jay Shetty, Lily Collins, Inter Miami, and as of this week, Diplo. Six of these individuals joined us just this year. Every one of them is a shareholder in Prenetics and because we want partners who care about what the company becomes over years. and the interesting thing also is that every one of these individuals reached out to us so which is a great sign that they've tried the product they they tested the product and then in October last month we went a step further you know we became the official nutrition partner of the NBA across Australia and eight Southeast Asian markets across 660 million people And this is also the first time ever the NBA has actually partnered with any supplement brand on a global basis. Next slide. Before we get here, I just want to talk about, again, partners open the door, but the product has to earn its place. And this is where the science comes into play as well. We have currently already a completed randomized control trial behind our flagship. We currently also have three further randomized placebo-controlled trials underway, two in longevity and gut health, and we expect to report the results by the first half of 27. The third trial that we have ongoing right now is an investigator-initiated study at Mayo Clinic in Florida involving 100 healthcare workers. So these are studies and not results and we will publish what we find. And of course, this is the evidence behind what we sell today. And now let me talk about what comes next. So IMA Hydration is planned for the first quarter of the 27th. We previously mentioned that we would launch Hydration Q4 this year. We moved the timing given Q4 is such a busy time with Black Friday, Christmas sales. We wanted to have its own quarter where we can promote one product and we'll do this in Q1. and what excites me is the feedback that we've been getting from all of our athlete ambassadors about our hydration product that have been already using it for many months. They keep coming back to it, they keep texting me for more, so I know it's going to be an amazing product. I've also been taking the product myself in the afternoon and it's become a routine I look forward to. So Hydration is the first of two launches next year. Care Bears by iMate is the second targeted for the second quarter of 27. So with Care Bears, what we did is we signed a 10 year exclusive worldwide partnership with authentic brand groups. We're gonna start with gummy multivitamins for children and adults. Over time, we plan to expand into better for you confectionary and wholesome children's snacks and foods. I'm personally excited about this because it brings our work into the family. Parents who grew up with Care Bears can introduce those characters to their own children through a daily wellness routine. We will operate the brand, recognize its revenue, and pay authentic royalty. And keep in mind, this royalty is not double counted by the royalties for IMEs. And as part of this partnership, Authentic will also become a strategic shareholder in Prenetics, a partner with deep experience building endearing brands. And yeah, Angela, can you just play that short video that we've launched about a few weeks ago just to give everyone an idea, the content that will be able to take place due to this partnership?
Care Bears character voice
Care Bears by IM8 promotional video character
Emergency Caring Council Meeting. To order.
Care Bears character voice
Care Bears by IM8 promotional video character
First up, our new self-care initiative.
Care Bears character voice
Care Bears by IM8 promotional video character
This should have been an email. We're launching Care Bears Gummy Vitamins.
Care Bears character voice
Care Bears by IM8 promotional video character
Let's go!
Care Bears character voice
Care Bears by IM8 promotional video character
But we're not science experts. That's why we're teaming up with IM8. Co-founded by David Beckham?
Care Bears character voice
Care Bears by IM8 promotional video character
Bro! Legendary!
Care Bears character voice
Care Bears by IM8 promotional video character
All in favor?
Care Bears character voice
Care Bears by IM8 promotional video character
Yes! Let's go! Absolutely.
Care Bears character voice
Care Bears by IM8 promotional video character
I'm in. Fine. Meeting adjourned.
Care Bears character voice
Care Bears by IM8 promotional video character
Care Bears by IM8, launching in 2027.
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Yeah, I mean, that just gives you a glimpse in terms of what's possible. I mean, I grew up with Care Bears. I know a lot of my friends grew up with Care Bears, and this will also take us into the retail shelf. And so that's going to be quite exciting as we expand there. Next slide. And as you can see, those are our new products. And starting with, and let me put next year in one picture, starting with what is in our guidance. As mentioned earlier, we're reaffirming our guidance of $400 million in 27. That's entirely built on our current two products our customers buy today. It includes nothing from our hydration category, as well as from Care Bears. About 44% of it comes from customers and channels we already have in terms of the $156 million you see on this slide here. And with about 19 million more coming from marketplace and B2B. That's before we acquire a single new customer in 27. So this is a forecast and a projection. And as you can see, there's two more moves that are planned beyond the launches and neither of that is also in the guidance. As mentioned, retail is also not in the guidance and we're developing Care Bears with a retail first focus along with a DTC strategy. The second big opportunity, which is also not in this forecast, is China, a supplements market of roughly $50 billion. We intend to launch in China by the end of 27. Both depend on finding the right partners and on the right local regulatory requirements. Now, kind of stepping back and kind of taking a look at how early we are. In under two years, we went from zero to a run rate of $284 million. That is 0.4% of a $200 billion global opportunity in a category. And this category has no dominant leader. On industry data, no company holds more than about 5% of it. If you think about 1% of our core markets alone would be more than a billion dollars a year in annual revenue, which is an illustration, not guidance. But it's also the other half of why we are investing now. So put it all together, next year for the first time, we will have three engines operating rather than one. We'll have our core daily nutrition business, hydration, and CareRares by iMate. I've personally never been more excited about what is in front of us, but I want you to judge us on what we deliver quarter by quarter. With that, Brian, let me turn it over to you to walk us through the financials, the cash position, and the outlook.
Brian Rosin
Chief Financial Officer Designate, IM8
Yeah, thanks, Danny. Good morning, everyone. Thanks for joining us. First, I'm grateful for the confidence that Danny and the board have placed in me and for Stephen for your great partnership through the transition. During the six months here, much of my work has gone into building a long, cost-effective financing runway for IMA's record growth for the quarters ahead and the years beyond. That includes helping secure the growth facility of up to $1 billion with general catalysts and gaining an intimate understanding of our customer costs, our returns, our cash conversion cycles, margin expansion opportunities. And today I'll show you a reflection of that continuing work. I'll focus on the results, how we funded the quarter, and what's included in our outlook. Unless I say otherwise, the financial figures I discuss here should be seen as Prenetics Group's continuing operations. Third quarter revenue was $64.1 million, up 37.9% sequentially and approximately 3.3 times last quarter, Q3 of 2025. As seen on the screen, IMATE revenue was 62.9 million, up 39.8% sequentially and approximately 3.7 times versus third quarter last year. Both figures came in just above the top of the ranges that we provided last quarter. IM8 now accounts for substantially all the group revenue, which also explains our moving to a single CFO structure. So those are the top lines. Let's walk through the full P&L next. Okay, so here's the whole quarter on one page that shows the strong progression of 2026. You'll note it's been a really strong story of expanding leverage on most areas of the P&L. We talked about revenue up 38% sequentially. Gross margin here of 64% in the quarter. Actually, it was a small step down. This was caused by a one-time inventory charge of $1.3 million related to older formulations. We've reformulated the product and this older formulations were written off in the quarter, which caused a slight step down. We expect the margin to continue at the 65% and to keep form beyond. Operating costs, so these are payments, people, R&D, and everything else we control. These fell from 25% of revenue in the first quarter now to 16%. So great leverage on this line that will continue. And this operating leverage is why contribution profit reached $30.6 million or 48% contribution margin. We publish contribution profit and contribution margin because it shows the profitability of the business before a single growth dollar is spent. Since spending those dollars as a capital allocation choice, we make deliberately and against historically very strong cohort returns. Below contribution sits the growth investment, as you can see there, $40 million of acquisition marketing, plus our royalty and ambassador cost lines that have now dropped to 5% of revenue combined in the quarter. That leads to an adjusted EBITDA loss of $12.7 million, or a negative 20% EBITDA margin, improved from negative 39% last quarter. That entire adjusted EBITDA loss is driven by the growth investments, and we gain nice leverage across the P&L in almost every other area. From there, that bottom table will take you to the IFRS net loss of $25.4 million. This is relative to the 9 million in Q2. You'll see that loss includes a $7.2 million non-cash fair value loss on our warrant liabilities. This charge will rise when our share price rises as it did in Q3. While you'll also notice that Q2 had benefited from a fair value gain as well as a disposal gain back in Q2. So of all those lines, of course, the one that deserves the most scrutiny is the $40 million of acquisition marketing. So let's turn to the next slide here and look at what that bought us. So as Danny mentioned, we saw our second consecutive quarterly decline in CAC, which is great to see. We acquired a cohort of 137,892 new customers, up approximately 16% versus prior quarter. The IMIT marketing spend was $39.3 million in the quarter, up approximately 10% from Q2, which leads you to a customer acquisition cost of $285, down from $301. Last quarter, when we reported, we had showed July was at 239. This was an unusually strong month for the brand. It was not a level we were planning around, nor do we plan around that number. The rest of the quarter, obviously, if you do the math, saw $28 million of spend at a $310 CAC. September, as Danny had mentioned, was a new record cohort with 52,696 new customers. Great month. Our new customer AOV was also flapped versus Q2 at 207. So consider what all this means. Since the first quarter, we've grown ad spend from just over 18 million on IM8 brand to 40 million in Q3, and cax have declined by 7%. At any scale, not to mention at tens of millions of dollars of quarterly increases, this usually goes the other way where CACs will usually go up, not down with that much more spend. This goes to show you how strong the brand is and how strong our marketing engine is performing. It also goes to show that despite the flexibility General Cattle's facility gave us to finance growth starting this quarter, we're continuing to remain really disciplined with our capital allocation. So next look at the general catalyst facility and how this works. So let's briefly remind ourselves on this framework. So as we announced in July, the customer value fund partnership provides a growth commitment of up to $1 billion. Of course, this isn't 1 billion of capital on our balance sheet. We draw against this 1 million over time against 70% of our acquisition spend each month. As each cohort comes in for that month that was funded, General Catalyst will receive 70% of the gross profit associated with that cohort each month as those subscriptions renew until they've recovered their principal. And then depending on how long it takes them to recover that principal, they'll receive a defined premium on top of that principal after the principal is repaid is when that premium is actually paid. And so what that premium is, if we look at the next slide, It depends on the speed of the payback. And so you can see here on the right side, the different ranges of payback speeds. And if we fall within those ranges, you can see the percentages there. Once a principal plus the premium has been paid for a cohort, general catalyst participation in that particular cohort ends, at which point then all the profit from those cohorts is ours and it had been pre-funded in a strong cash flow sort of way. This structure allows us to fund the portion of acquisition investment with the future receipts each cohort's intended to generate. Also a reminder, this financing was non-dilutive. This cost of the financing is really just this premium share that we're laying out here on the right side. That's the only cost of it. Since their return generates, since their return rather depends on the same two numbers that we manage the business by, what a customer costs to acquire and what each cohort returns, disciplines inherently built into the way that the growth is financed and so in that way it aligns our incentives with the facility. So turning to the next slide, since this is the first quarter that General Catalyst will show up on our financial statements, I thought it would be good to actually show here specifically in Q3 where to look for them so you can go look for yourselves. On the P&L, the entire footprint is in the financing cost section below EBITDA. So revenue, gross margin, acquisition marketing, all those things are completely unaffected by the General Cattle's facility. All you'll see is the $0.8 million of effective premium accrual in financing costs. This is below adjusted EBITDA. On the balance sheet, You'll see that the $34.7 million is there. That's the borrowings, which includes $31.6 million that we received in net cash fundings. And there's $2.3 million of true-up that was owed by General Catalyst at the end of the quarter that was settled in October. And then there's $0.8 million of accrued finance costs also within that line on the balance sheet. On the cash flow statement, you'll see this come in as cash from financing. And so as it relates to adjusted free cash flow, which is a non IFRS metric, This is our operating cash flow, which in the quarter is negative 27.5 million. Net of capex, which for us is zero in the quarter, plus the GC funding of cash, which was that 31.6 million of inflow, which puts our adjusted free cash flow for the quarter at 4.1 million positive and our ending cash balance that increased for the quarter. So let's turn to the balance sheet and look at that real quick. So September ended with $111 million of cash and current financial assets, up from $109.4 million at the end of Q2. That total comprises of $63.4 million of cash and cash equivalents and $48 million of current financial assets. Inventories increased to $20.1 million compared with $14 million at the end of Q2. We also separately increase deposits and supplier prepayments with our manufacturers to prepare for the holiday quarter and the products planned for next year. The balance sheet contains the $34.7 million of borrowings under the General Catalyst Agreement as we saw in the last slide. And so for the first quarter of availability, the partnership really performed exactly as we intended it to. We were able to grow cash balance in a quarter when one, we spent a record marketing investment to acquire our largest quarterly customer cohort we've ever had. And two, it significantly bolstered our inventory reserves in preps for a big Q4 and into next year, especially with some new product launches. So next let's turn to our outlook. We are reaffirming our full year 2026 total revenue guidance of 220 to $230 million, including IM8 revenue of 215 to $222 million. Subtracting the nine months we've reported from those figures, the fourth quarter works out to approximately 73 to $83 million for the group, and 73 to 80 million for IM8. We expect a second half adjusted EBITDA loss of 30 to 35 million dollars compared with a negative 8 to 12 million dollar range that we gave back in August as Danny mentioned. With that 12.7 million in Q3, the range implies a fourth quarter adjusted EBITDA loss of roughly 17 to 22 million dollars. This loss is bigger in terms of dollars, but as a percent of revenue, it actually improves from 31% in the first half to 23% in the second half at the midpoint of our guidance. Within the second half, more of it falls in the fourth quarter, about 25% of revenue as an adjusted EBITDA loss versus 20% adjusted EBITDA loss in Q3. This is deliberate increase in customer acquisition spend that we're planning in Q4. It's also a typically a little bit more expensive period and we're making it from position of strength. We ended September with $111.5 million of cash and current financial assets up from June in a quarter of record spending. General Catalyst finances 70% of our acquisition spend, and so we have our balance sheet set for new products, clinicals, and the brand. We're making this investment going into the holiday quarter and ahead of next year's product launches. The returns are evidence that all this is working. Three to one is the ratio of lifetime value to acquisition costs that we manage the business toward. Our earliest customers are way past that 4.1 times, as Danny mentioned, in under two years. And then the next 91,000 customers are at 2.7 times, and those will pass the 3.0 mark by early 2027. CAC has also declined two straight quarters, as we mentioned, and so we will look to continue investing in Q4 for the same reason for as long as our returns will hold. We expect adjusted free cash flow to remain positive in Q4 again, despite the negative operating cash flow due to the general catalyst financing. We're also affirming IM8 annualized revenue run rate to hit at least $300 million by year end. and our operational investment focus for Q4 is delivery against the demand while preparing for our exciting product launches that we mentioned earlier. For 2027, we're reiterating our revenue guidance for IMA to $400 million or more on the current product catalog. This includes no revenue from hydration, Care Bears, other products, retail or China. So all of that is upside to the current guidance. Of course, as Danny showed, that forecast, none of it is earned. We have to remain focused on retention, efficient acquisition and execution across the year. Lastly, for the first time, we're publishing a long-term financial framework. This is a question I get asked a lot about, what does the business as it matures start to look like from a margin standpoint? And so I thought this would be really helpful to show. Over time, we'll be targeting a gross margin of 70% to 75%. will be targeting operating costs of 8% to 12%. Brand royalty and ambassador costs should drop to 3% to 5%. And our acquisition marketing should drop to 35% to 50%, which would put you to an adjusted EBITDA margin of 15% to 25% for the business as it matures. You can see just through the progression in 26 that we're well on our way towards these numbers. Still quite a bit of work to do and none of this is guidance and we don't have a set timeline on any of this, but this is what you should be looking for us to be moving towards on all these lines. Gross margin in particular, we've onboarded a new third-party manufacturer in Q3. They will come online in Q1. With that, we're going to be adding additional capacity and lower production costs. So our gross margin is expected to improve in the early part of 27. We're not yet ready to say specifically what the guidance for gross margin will be yet in Q1. Look for some of that next quarter. Our operating costs don't rise with every quarter. And so that will allow us to really gain some more leverage. Royalty and ambassador costs are the same way. And then acquisition marketing will of course fall over time as our subscriber base grows and as more revenue comes from our existing base. Again, to be clear, these are not long-term targets and not guidance for any particular period, but hold us to these metrics as this is what I'm looking to drive us towards. Moving our finance leadership to the U.S. brings us closer to our largest market and primary capital market. Cindy Tatt joined us in August as our VP Financial Controller. She's an important part of our build-out, and you can expect us to continue adding experienced U.S. leadership in the coming quarters. Thank you to all of our Prenetics and IMA teams for their tireless support, and thanks to all of you for joining us today. I'll give it back to Danny now for closing remarks, and then we will open it up for questions.
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Thank you, Brian. Before we open up for questions, let me leave you guys with a few points. Revenue is growing, cash is growing, and a community of people who trust IAM is growing faster than ever. Very, very few companies get a window like this, least of all in a category as crowded as supplements. A brand that is getting stronger every month, a partner financing 70% of what we spend on acquiring customers, and data that shows what every cohort returns. We are building for the long term, and the path is very clear. New products, new sales channels, new marketing channels, and deeper international markets. We can be profitable tomorrow if we choose to be. Right now, we're choosing growth. We also have a very detailed shareholder letter and investor deck of 70 pages and suggest everyone to look into that and review that. For now, thank you everyone, our customers and our shareholders and everyone who joined us today. I'm happy to take questions from anyone.
Shannon Devine
Host
Thank you, Danny and Brian. We'll now open up the floor for questions. If you'd like to ask a question, please use the raise hand function at the bottom of your Zoom window. I'll then announce and please unmute yourself to ask your question. We'll get to as many as we can and pause now while we allow for people to queue. Our first question comes from Eric De La Race of Craig Hallam. Eric, you may go ahead.
Eric De La Rosa
Craig-Hallum
Great, thank you for taking my questions. Congrats on another strong quarter here. So both China and retail, some nice updates there. I just would like to unpack both those opportunities. Can you just help us understand what needs to be done before you launch into both China and retail, whether that's new investments you need to make, capabilities you need to develop or relationships you need to develop? Can you just help us sort of understand the pathway to both entering China and then your plans for entering retail as well?
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Sure, I'll start with the retail piece because to be fair, that's probably less complex than China. So retail wise, the interesting thing is with our current two product skills, we've actually been, I would say every single major retailer in the US has inquired for us to get into retail. And we haven't done so yet because we haven't felt like it was the right product yet. But with Care Bears and hydration products, these two products being less expensive than our current skills, we feel this is much more targeted at a retail opportunity. And so we are speaking to all the big box retailers right now. and we do expect to be in retail shelves by the end of 27. So of course, we haven't had any experience in retail in the past, but we haven't had experience doing DTC and we've been able to accomplish amazing things with that. So our capabilities, we do believe are very transferable to the retail. We will definitely need to hire a few new people in the US to be able to manage that retail big box relationships. but we're very confident that we can do so. China-wise, again, China is a much, much more complicated market. So we're working with a few different potential partners to enter China with people that know the market, know the industry, Again, because in China, the way it works is no one actually transacts on your own website. Everything is through third party, Tmall, JD, Douyin, RedBulk, etc. But again, given my resources, my network there, I'm very confident that we'll be able to identify a very trustworthy partner and be live in China by the end of 27.
Eric De La Rosa
Craig-Hallum
All right, that's a great color. I appreciate that. And then just last one for me. Can you just talk about some of the dynamics impacting customer acquisition costs? So, you know, obviously it's nice to see the sequential declines. It was down in July and then up in August and September. Just what drove some of those fluctuations and how should we think about those dynamics going forward?
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Yeah, I think the dynamic is going forward because there's always going to be fluctuations depending on monthly, quarterly, the renewal process. So that's why moving forward wise is much better to understand on a quarterly basis in terms of our CAC. So I think the great thing about the CAC is that you see for at least the two sequential quarters, our CAC actually declined. And if you look at Q1 to Q3, our spend more than doubled while having a reduced CAC. So we feel that's a very significant figure because typically when you're spending so much, your CAC, almost every reason it continues to go up, then we've been able to reduce that. And so that gives us even more confidence to continue to invest into growth. Again, given in terms of investing growth, reality is every single new customer that we're acquiring now primes us to be even more successful when we're launching hydration, Care Bears, we'll get much more brand presence when retail hits. And so in many ways, we want to be much more aggressive now in this investment opportunity, given that we're seeing so strong returns.
Eric De La Rosa
Craig-Hallum
And just in terms of how we should think about that going forward, do you expect these sort of broad, you know, this sort of call it roughly 300 level? Is this the right way to think about it for, you know, just call it the next couple of quarters? Obviously some of this can fluctuate, but is this sort of the right range that you're continuing to see?
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
I think that's the right range. You know, I would say within, 10 to 15% range within that $300 mark, right? Because again, depending on seasonality. So as I'm sure you know, in Q4, everyone's going to be bidding up against acquisition, bidding, auctions, and et cetera. And then in Q1, and of course, there's also going to be opportunities from a decrease when we do certain offline events. So all of this put together, but I would say roughly 300 plus or minus 10 to 15%.
Eric De La Rosa
Craig-Hallum
That's very helpful. Thanks again for taking my questions and congrats on another strong quarter here.
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Right. And then keep in mind with the CAC wise, one thing is that's also very interesting because if you just look at a CAC that's been increasing over the last, you know, let's say three to four or five quarters, a key component of that, our CAC has increased, but our average order value has increased very significantly too, right? So our average order value is now well above $200, you know, where again for a new customer coming in is quite significant.
Eric De La Rosa
Craig-Hallum
Yeah, absolutely. Yeah, another great sign. Thanks for taking my questions.
Bill Sutherland
StoneX
Thank you, Eric.
Shannon Devine
Host
Thank you, Eric. Our next question comes from Bill Sutherland of StoneX. Bill, you may proceed.
Bill Sutherland
StoneX
Thank you. Hey, good morning, guys. I wanted just to, I don't think he discussed the marketing channel strategy going forward. Can you just update us on what your plans are there?
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
sure so we've actually so on the marketing strategy so um i think i mentioned this back in q2 right so we are predominantly meta uh focus right so in the last quarter last two quarters we've actually been diversifying away from meta so we've started yeah tick tock we started app loving we started uh snapchat we started x uh you know next month we're going to be doing connected tv linear tv and so we're expanding to a lot of these different channels which ultimately will diversify our revenue base and be less dependent on meta because at the end of the day if something were to go wrong with meta then yeah that's not a good sign right so having this diversification already in place and we're seeing strong signals across all these other channels which is also a very positive signal for the business because we're able to tap into new audiences across multiple channels
Bill Sutherland
StoneX
Are you kind of in test mode at this point, Danny, with those other channels? And would you expect just better performance overall with a diversified mix?
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
I would say some of these are still in test mode but of course some of these have already passed beyond test mode but that's where I do believe a big reason why you have seen our CAC actually drop basically since Q1 is the diversification of all these channels right if we just stuck to meta alone our CAC would have you know went very very high but because of this diversification we're getting much more efficient in the marketing aspect of things right and we do believe when we get into retail yeah that will also be another channel where I think we'll have even greater efficiency
Bill Sutherland
StoneX
And then one last one for me, the performance with the earliest cohorts, clearly very strong. Is there any reason that we shouldn't think that the latter cohorts, I'm just thinking about the higher acquisition costs, et cetera, that the latter cohorts won't exceed the three to one, just like you're seeing on the early ones?
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Yeah, so we have every reason to believe it'll follow the same pattern as our earliest cohorts, right? So if we look at the earliest cohorts, it's already returned at 4.1, and this is actually less than two years. The next 90,000 individuals, which are the Q2 and Q3, again, they're already at 2.7, and they're going to be approaching 3x in early 27. So we have every reason to believe that it will also approach similar. And keep in mind, all these earliest cohorts only had two products, right? And in the future, we're going to be releasing more products. Again, in the first half of 27, there's going to be hydration. There's going to be the gummies for kids and adults, right? So yeah, you should actually expect to see this continue against even our latest cohorts.
Bill Sutherland
StoneX
Great. Thanks for the update, guys. Thank you, Bill.
Shannon Devine
Host
Thank you, Bill. We'll go next to Susan Anderson of Canaccord. Susan?
Susan Anderson
Canaccord Genuity
Hi, can you hear me?
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Yes. Hi, Susan.
Susan Anderson
Canaccord Genuity
Hi, good morning. Nice job on the quarter. I guess I wanted to maybe just ask around the marketing around the new products that you're rolling out, particularly as they go into retail, such as like the Care Bears. I guess just curious, you know, what the plans are around marketing, if it's going to be a similar marketing strategy for your current core products, or will you switch it up just given that some of it will be going into retail? Thanks.
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Yeah, I mean, you know, of course, there will be a difference in terms of offline marketing wise, right? So we're going to be doing lots of offline activations, you know, together with the big box retailers, there's going to be a lot of end cards available at the, you know, at the offline retailer. So we're going to be also driving a lot of online to offline traffic, which we haven't done before. But I think the great thing is that, again, with Care Bears and the hydration products, these are already, yeah, I would say at least in the wellness supplement category, two of the most sought after products that people search in retail. And then again, going back to all of the brand investment that we're making now, when we are in retail, people will recognize IMA already. Because the last thing you want, and a lot of the reasons, again, I study a lot of this stuff in terms of go-to-market strategy, is when a brand gets into retail and There's no demand, right? And you need to be able to drive that demand because no one recognizes that brand. So I think a lot of the brand equity, the brand investments that we're making today are going to pay off significantly when we get into retail channels.
Susan Anderson
Canaccord Genuity
Yeah, okay, great. And then maybe just one follow-up.
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
I was curious, just kind of the traditional- And then also, Susan, one other thing I can add that's also gonna be a big plus for us, right? And for CareBears specifically is that, you know, next year is CareBears' 45th anniversary. So by default, Care Bears by themselves are going to be doing lots of offline physical activations online as well. So that's naturally going to help us in terms of brand recognition or people understanding the brand better.
Susan Anderson
Canaccord Genuity
Yeah. Okay, great. Thanks so much.
Shannon Devine
Host
Thank you, Susan. Our next question will be from Jonah Kim of TD Cowan. Jonah. Jonah, please unmute.
Jonah Kim
TD Cowen
Can you hear me?
Shannon Devine
Host
Sorry.
Jonah Kim
TD Cowen
Hi, thank you for taking my question. Hi, Danny. Hi, Brian. On the IMA itself, how do you think about the distribution opportunity going forward? Is there room to expand in the retail? Would love any color there. And the second question, as you continue to grow your base of brand investors, how do you plan to leverage that going forward? Is your strategy different as you look towards next year? Thank you.
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
So as mentioned, we definitely plan to go into retail. Again, I think even from an investor perspective, this makes the business much more investable because we're not just a direct-to-consumer brand. People will be able to see us on the shelves. So as mentioned, by the 27th, we will have at Lisa Hydration and Care Bears brand inside retail. So you're 100% on retail. And in terms of our ambassador relationships, and we look at a lot of our ambassador relationships on a case by case basis. And as I mentioned earlier, every single one of these big ambassadors that comes in, yeah, they were actually, yeah, they founded us. And normally it's through a recommendation by their nutritionist or doctor or a friend. and they're taking the product they're enjoying the product they're using the product daily and they come find us and you know so I think these are the best type of partnerships where these ambassadors they start off as users first and they come in and they want to partner with us and then so you know a lot of people ask me you know who who are we going to sign up next and and the reality is I don't know who's going to reach out to us next And then so once they reach out, we see if it's a fit for the brand. Of course, it also has to fit in terms of the commercials, but because these individuals love IME so much, we're always able to get really good partnerships out of these.
Jonah Kim
TD Cowen
And just one last question on obviously New Year is an important period for wellness products and you're at a larger scale. Is there anything that you are doing different in terms of your marketing strategy around the New Year time?
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Yeah, I mean, I would say Q4 and Q1, right? I mean, Q4 and Q1 are going to be the biggest seasonality aspects in the business-wise. So Q1, again, new year, new you. So we will be launching hydration products in Q1. So I think that's going to be different along with our current essentials and longevity products. One key thing I think you can see us continue to do is that we're continuing to do a lot of offline activation events and you'll continue to see that especially when we launch Hydration because naturally there's going to be many multiple flavors and then our offline events again since you know 22 months ago and that's one thing that really separates us from everyone else is that people can see the product they can talk to our scientific advisory board they can talk to our ambassadors I meet with them so we've done now 200 plus events in the last 22 months and that really puts a you know kind of like a face to the product as well and then so I think with hydration we're going to do more of these type of activation events you know around the world
Jonah Kim
TD Cowen
Thank you for the call.
Shannon Devine
Host
Thank you, Jonah. We'll go next to Alex Novak of Lucid. Alex, you may proceed.
Alex Novak
Lucid Capital Markets
Okay, great. Good morning, everyone. Thanks for taking the time. Appreciate it. So we talked a lot about the CAC throughout the call, but I just really want to keep it simple. You raised the second half loss due to the higher marketing spend, and you raised it because you clearly see the potential out there and you want to keep pushing hard. I get that. But how come we didn't raise the revenue guidance either for Q4 or for next year?
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Brian, you want to take that one?
Brian Rosin
Chief Financial Officer Designate, IM8
Yeah, I mean, we have a fairly wide range there. Just given that Q4, you know, we filled the funnel up with a lot of customers that are aware of us from the Q3 push. We have a lot of customers in our mix now that hopefully will pull through as Black Friday comes around. and so you know rather than us raise the revenue guidance we we decided to keep the fairly wide range there and hope that you know that that's sufficient we also don't want to raise the mark you know too high to the point where we are you know unsure of how that that will look and so we feel confident with the with the revenue guide there just being a pretty wide range already
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Yeah, and I would also add is that if you think about where we are today, again, you know, the brand is 22 months old, right? This year, in our second year, we've already achieved, we're achieving 220 million plus in full year revenue. And next year, we're targeting 400 million in our third year. At least in the supplement category, no company has ever done that in such speed and such growth. So we feel we are at a very good point already. And we want to leave some upside up there. Again, hydration, we believe, is a big category. Care bear is a big category. But we're so focused on growing the business today with new product development, growing existing business. We just felt at 400, it gives a lot of... Investors, upside opportunities for us to capture on that.
Alex Novak
Lucid Capital Markets
Yep, absolutely. Even your shareholder letter mentioned the plan behind 2027 sums to more than $400 million, so totally get that. I do want to go back on our prior point about partners, and you've added some really good partners. I'm super excited about the potential within the running community, just given the new hydration launch. and I know you can't or the the goal here is a partner uses it first and then comes to you but you also get to you know focus a little bit more on certain channels what else are you targeting in particular like any particular sports that you would love to get a partner for any certain celebrity niches that you're looking for yeah to be fair I think we've gotten um if you look at our roster of of athletes and individuals right it's quite diversified already
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
and we want to be able to do more with our existing individuals. I think one thing that we are looking for, I mean, I wouldn't say looking for it. I think if we had one niche where we haven't, I think it's when we think about China. So we are looking to a few different individuals that can really help us push the envelope in China for when we launch in 27. But besides that, again, every day spins. It's been crazy busy, right? And then so I think we're very excited and happy with our existing roster. So I can't tell you that there's like a specific new area that we're looking to from an ambassador partnership perspective. And like you said, Alex, I mean, the running club piece is a huge opportunity for hydration, right? I think around the world, you see running clubs being developed regardless of 50 people, 100 people. I mean, Diplo's running club is now 10,000 people. He's only started this like a year ago. So that's a prime opportunity to be able to promote our hydration product when it comes out in Q1.
Alex Novak
Lucid Capital Markets
Absolutely. All right. Well, thank you for the time. Appreciate it.
Shannon Devine
Host
Thank you, Alex. Our next question comes from Ryan Myers of Lake Street. Ryan.
Ryan Myers
Lake Street Capital Markets
Hey guys, thanks for taking my questions. First one for me, you know, just on the topic of the general catalyst financing with the, you know, financing now operating for a full quarter, how should we think about the relationship between new funding and repayments as the facility matures? And then, you know, maybe at what point do you think the business can begin generating positive operating cash flow independent of the general catalyst funding?
Brian Rosin
Chief Financial Officer Designate, IM8
Yeah, so I mean, in the quarter, we repaid 7 million against draws of 31. And then they owed us a few million at the end of the quarter as well. And so for quite some time, the amount that we're going to be drawing down for each individual month is going to exceed any of the repayment amounts in aggregate for a good amount of time. And so as you look out and you model the business into the future, it's more like, you know, I would say 18 months into the arrangement is when I start to see the cash coming in more or less equivalent to the cash being repaid to them. So at that point, it becomes cash neutral. However, though, cash neutral is a much different environment than us funding our own acquisition dollars at that point in time. Thank you for joining us. We've not wanted to get too far ahead of ourselves in trying to guide when specifically that will happen. Depending on how you model out the business, it becomes pretty difficult to outrun the math of how big the existing customer base is and how much contribution, profit, and dollars you're getting from your existing customer base. We have 160,000 subscribers right now. That number continues to go up. And so your existing repeat revenue is going to continue to get so large that unless we continue to spend significant amounts, sequential growth, period over period, it eventually becomes too hard to outrun the math of no matter how big we want to invest, when we want to hold ourselves to the three to one return on that. you'll reach a world where we'll cross the chasm to profitability. And that will, you know, again, we don't want to put any specific timelines on it, but I would say it's not that far out into the future when that would happen. And it all comes down to how much are we able to keep spending at our three to one return at, you know, near our 300-ish CAC. We've been able to keep spending more and more at that number. And as time goes on, if we can continue to do that, then that'll just keep pushing out that chasm. But if we slow the growth or we slow the spend, that number would come very fast. I mean, we could become profitable next quarter if we slowed our spend, but that's not in the best interest of our shareholders long term.
Ryan Myers
Lake Street Capital Markets
Okay, got it. And then, you know, secondly, maybe for Danny, can you just sort of provide us with some commentary on what you think is allowing, you know, the IM8 brand specifically to drive the above average customer retention when it comes to supplements?
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
I mean it's quite simple actually right on that part yeah because the product the product works yeah and I think you know we've again starting from day one wise right we had an amazing scientific advisory board third party testing NSF certification and then so when you drink it over a long period of time you form routine it works and you'll continue with it And so I think that's the main reason why I think retention has been so powerful, right? And I think we've also really focused not just on the functionality of it, but at the same time, also on the taste. When we just launched, we had one flavor. We've now introduced two new flavors. In Q1, we're going to introduce another flavor. So I think having these new updates on the formulation as well as on taste continually delights our existing customer base.
Ryan Myers
Lake Street Capital Markets
Makes sense. Thanks for taking my questions.
Shannon Devine
Host
Thank you, Ryan. We'll go next to Tom Forte of Maxim. Tom.
Tom Forte
Maxim Group
Great. Thanks, Shannon. So Danny and Brian, thanks for taking my questions. I have two on artificial intelligence and I'm going to ask them at the same time. So can you give an update on how you're able to leverage artificial intelligence to scale the business without adding material headcount? And then second, on agentic commerce, Metis had tremendous engagement based on the number of downloads for Muse. How are you positioning yourselves to capitalize on that opportunity?
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Great question, Tom. Good to connect. So I think on the first part, in terms of how we're using AI, I think, again, if you look at Yeah, at least in direct to consumer space, right? The key thing is actually for any company in this space is content. You need to have lots of content across many different channels. And a lot of the aspects that we do use is basically utilizing AI to develop lots of content regardless if it's static videos in combination with real shot videos and basically utilizing AI to cut them through to much more different content pieces. So for example, One of the clear examples, I think I shared this previously, is that if you look at our meta public ads library, at any given time, we'll have 3, 4, 5,000 ads running live at any given time. And then what we'll do, we'll be able to utilize AI to identify the winners very fast. And when we do identify winners, we'll then show these same ads on App 11, on X, on Snap, on TikTok, the same aspects. And then on a weekly basis, we're also testing a lot you know with new content five six seven hundred pieces of content on a weekly basis which you know to be fair if you don't know what you're doing it's very very difficult and so that's why there are very few brands that can scale at our levels right so i think that gives you a clear example so that's why again even right now if you look at Our overall team base, we have approximately 70-75 employees. So if you think about our full year revenue this year, which is going to be well more than $200 million, so it's roughly about $3 million revenue per employee per year. If we think about next year, looking at 400 million plus, we'll probably add 25, 30 people. So probably get to about 100 employees at 400 million. So that would be roughly about 4 million per employee per year. So we believe which are great metrics, right? In terms of the agentic commerce piece, great question. So right now we're actually testing in terms of even having ads within ChachuBT, which they've already opened up. I do believe it's still early days, but it's going to move very, very fast. So I do believe within the next three to six months or even a shorter pair of times, a lot of people are going to be using their AI to purchase things. Even for me, I'm using Muse, Instinct to buy things with AI. So I couldn't imagine that's going to be a common place in the next three, six, 12 months. And again, given the amount of work that we're doing with AI, we feel that we'll be able to lead the pack in that area. Thank you, Danny.
Shannon Devine
Host
Our next question will come from Dylan Hines of B Reilly. Dylan, please go ahead.
Dylan Hines
B. Riley
Hey, great quarter. Thanks for taking the question. I just wanted to go back to the retail entry. I was wondering, do you already have agreements with retail partners? And could you provide any color on that, maybe which ones? And then what would the ramp look like when you expect, you think you'll include this, the retail launch into guidance?
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Yeah, so I think in terms of the retail aspect, Transparent, we do not have any agreements. So we've been again, we've been hounded by all the major retail partners, I would say, for the last 12 months. So this is something that I'm personally involved with in terms of working closely with that big box retailer. And again, we can't mention the name, but it's your... I mean it's a big name in the US retail space right and we expect that to go live by the end of 27 and I do believe right now is still way too early to provide any type of guidance in terms of you know what that is but again for us wise we're very optimistic about the opportunity given this big box retailer and our product scope and our product set that we have in place And of course, once we're in retail, I think very soon we'll be able to give guidance in terms of how big the opportunity is.
Dylan Hines
B. Riley
Okay, gotcha. And then going to the ambassador network, I guess, do you have any specific plans in terms of activations with the ambassadors? I guess, how do you convert clients? The following visibility and subscriptions. Can you try to quantify any of the benefit from the ambassadors?
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Yeah, 100%, right? So I think every single one of our ambassadors have more than paid much more than what we've given them. So it's actually quite easy for us to quantify. It's not just from the off. To be fair, the offline activations is more brand activity events. Yeah, but you know, for example, when we have a partnership with, you know, Yannis, Arena Sabalenka, and etc. One of the key things for us is content and digital profiling. So we're able to utilize partnership and whitelisting ads. You know, for example, Yannis, he has, you know, 20 million followers on Instagram. So we can market from Yannis' handle, Arena's handle, you know, to their followers, right? So we can directly measure, Thanks for taking the question.
Shannon Devine
Host
Thank you, Dylan. Our next question comes from George Kelly of Roth. George, please go ahead. Hey, everybody. Thanks. Can you hear me?
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Yes. Hey, George.
George Kelly
Roth Capital Partners
Hey, Danny. Thanks for taking the questions. A couple for you. I'll start with, I think I heard in the prepared remarks that you're changing manufacturing partners. Did I hear that right? And can you give just the reasoning behind the change? Maybe it's related to the gummies or pricing. Not sure. So any detail there would be helpful.
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Yes, well, for the manufacturing partners, actually, it's a new manufacturer partner we're bringing in place for our hydration product, as well as adding additional capacity for our existing products. And of course, for the gummies, that's going to be a separate manufacturer as well.
George Kelly
Roth Capital Partners
I guess for the core product, though, are there changes coming?
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
For the core product, we're adding additional capacity. Because right now, our scale is where we can't just be dependent on one manufacturer. So we're also adding another manufacturer just in case anything happens.
George Kelly
Roth Capital Partners
Okay, understood. And then second question from me. Back to your guidance revision, the EBITDA change. Is it fair to say that, like, I guess I'm just trying to dig into the trends you've seen with respect to CAC in October and November. And I'm wondering if there's been something that maybe wasn't sort of fully appreciated in your prior guide. Maybe it's the election or just trying to understand sort of how CAC has changed versus your earlier expectations.
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Um, I mean, it hasn't changed much on a core, I mean, again, on a quarter to quarter basis, right? So I think, you know, CAC was roughly about, you know, $285 in Q3. And then so again, we believe it will fluctuate within 10 to 15% of this range, roughly about, you know, $300, right? So we feel if we can maintain our spend our CAC at current levels you know we are in a good spot and the reason why we're in a good spot is because we know at this level of CAC we'll be able to get payback within approximately six months and we'll also be able to achieve that three to one ratio over a 36 month period of time okay
George Kelly
Roth Capital Partners
Okay, maybe if I could sneak in one more quick one. The updated gross margin target, the long-term target of 70% to 75%, how much visibility do you have on that? And are these manufacturing changes and the new products and stuff a big part of it? It's a big jump, so I'm trying to understand your confidence.
Brian Rosin
Chief Financial Officer Designate, IM8
Yeah, there's two parts. There's one that's on the manufacturing side and there's the other piece that's on the fulfillment side. In both of those areas, I think we have identified some fairly low hanging fruit of, you know, as we get more economies of scale, we'll be able to get, you know, better pricing on some of those areas. And so I would say, you know, we haven't figured out how to get to the upper range of that target. It's pretty clear to me how we're going to get towards the bottom part of that range with, you know, some work to be done for sure, but fairly straightforward to get there, you know, within, you know, four to six quarters, I would say. Again, not specific guidance, but I would expect us to approach the lower range of that 70% number towards the end of next year at some point. And then towards the 75, as the business continues to grow and as we bring on additional capacity, you add some, again, more economies of scale on both parts of it, again, manufacturing and logistics. I think that we would be shooting for the upper range eventually, but the lower end is clearer in sight right now.
George Kelly
Roth Capital Partners
Okay, thank you.
Shannon Devine
Host
Thank you, George. Our next question comes from Kyle Bowser of Titan. Kyle, please go ahead.
Kyle Bowser
Titan Partners
Thanks for all the updates here. Maybe my first question is around price elasticity and any kind of competitive dynamics. You've obviously taken significant share from the top players and we also saw that 87% of new IMA customers had no observed purchase from IMA. AG1 Gruins or Thorne before their first IMA order. So just how have the pricing competitive dynamics been out there? And obviously you've got a premium price on yours given the superior product, but should we expect kind of continued pricing stability?
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Yeah, I mean, we haven't seen, you know, much price issues for us. I mean, again, we haven't changed our pricing, you know, since we've, I mean, actually, since we've launched, we've actually had a slight price increase. But we haven't seen any issues in terms of price elasticity or any type of demand, as you see evidenced by the continued growth on a quarterly basis.
Kyle Bowser
Titan Partners
Got it. And maybe just around the clinical trials, can you talk a little bit more about how this might be unlocking new segments of the population? Obviously, consumers are getting much smarter and awareness is certainly building. Do you anticipate results driving new cohorts of consumers or maybe driving clinicians to recommend the product more? Just kind of curious how you'll leverage that data.
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Yeah, so I think at the end of the day, I mean, again, we're probably one of the only supplement brands to actually launch our clinical trial before we launch the brand and the product, right? And then, so again, all of this adds us much more credibility and trust to that consumer. So of course we'll be able to leverage that in terms of marketing, A lot of marketing and also, like you mentioned, clinicians will be able to prescribe it much more. So, you know, very, very positive and hopeful about these trials that are going to be releasing in the first half of 27.
Kyle Bowser
Titan Partners
Excellent. Well, thanks for all the updates. Right.
Shannon Devine
Host
Thank you, Kyle. And our last question comes from Alex Hantman of Sidoti. Alex, please go ahead.
Alex Hantman
Sidoti
Thank you, and thanks for taking questions. I just wanted to start with repeat orders. You know, they were looking great, 59% of customer billings this quarter. And I'm curious, as that share grows, how quickly does acquisition marketing come down towards your 35 to 50% range? And what does that mean for the timing of profitability?
Brian Rosin
Chief Financial Officer Designate, IM8
Yeah, so the 59% is nice to see. However, if we can continue to invest at the three to one, we'd rather keep spending more and more into new customers. So it's a conundrum in that when we spend more on customer acquisition, Your percent of new revenue is higher, but that's a great sign for the future with the returns that we have. And so I would again say that profitability is not necessarily a goal. It's inevitable with the math that eventually it just becomes too hard to outrun it, as I mentioned a little bit ago. So it's hard to put a timeline on it because we've exceeded kind of where I would have expected us to have been able to spend up to at a CAC that's declining. If that continues, then of course we'll continue to do that, at which point you push profitability out. If we start to slow the spend, it brings profitability forward in the nearer term. But yeah, it's too tricky to try to say specifically when that will happen because we've been exceeding what I would have thought we could have been spending. And again, with new products and all that, we don't know how those are gonna impact CAC. We don't know how it's gonna impact You know, overall LTVs and LTRs. And so, you know, we need to get these products launched before we'll be able to kind of model into the future more specifically around profitability target. But, you know, I would expect that the marketing will continue to come down as a percentage of sales, which we saw it already, you know, from Q2 to Q3. I would expect that to trend mostly down, like there might be some blips here and there, but mostly that will keep trending down to that range that we gave for longer term.
Alex Hantman
Sidoti
Okay, helpful context. Thank you. And speaking of new products, I know, you know, hydration launches into about 160,000 active subscriptions, you know, it's a big number. So I'm curious, what attach rate would you consider a success in year one if you have a target? And also, you know, about how margins might compare to the core products?
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
I would say hydration and gummies were the two categories that when we did surveys with our existing customers that they asked about that they wanted us to provide. So yeah, I would expect a minimum of 15 and 20% against our existing subscriber base in terms of that will take up this. And I think also not just our existing customer base, right? The reality is Electrolytes Hydration is a huge category. It potentially is even bigger than our existing supplements or daily nutrition category. So I think we'll also be able to get a lot of new people into the door that we can also cross and upsell them with our current essentials and longevity products.
Brian Rosin
Chief Financial Officer Designate, IM8
And then from a margin standpoint, just to touch on the margin of those. So the margin profile will be very similar to our current business margin from a product cost standpoint, for sure. From a logistics standpoint, it depends on if we can trade people into a multi-month or a bigger basket size and attach, whether it's our current products or an essentials bundle. or if you're getting a three month supply of hydration, for example, that will allow the margin to keep really in line with where we are today. If we're seeing AOV start to decline because people are taking more of the one month supply of hydration, which is a lower price point off the door than our current assortment, you might see a little bit of margin pressure just on the fulfillment side alone it costs us more or less the same to ship a product to a consumer if they buy fifty dollars worth as if they pay a hundred dollars and so you'll see a bit of pressure potentially depending on how AOV looks but we'll be trying on the D2C channel for sure to get people into a multi-pack which would alleviate that pressure entirely. And then the retail piece is also the other unknown there. The retail channel looks different from a margin profile as you can imagine. Much lower cost on the fulfillment side, much lower cost on the actual ad dollar specific going into retail. And so as I model it out, I think the margin of the total new products will be very unchanged versus the current. There's gonna be some pluses and minuses there, but overall I wouldn't expect it to be pressured much.
Alex Hantman
Sidoti
Very helpful, thanks for the color. And then last one from us, I know we've spoken about retail at length, but the 2027 bridge also includes about 19 million from marketplace and B2B. I know that's only about 5% of revenue, but I wanted to hear a little bit more about the B2B opportunity looks like and how fast perhaps that could grow from your perspective.
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Yeah, so in the marketplace aspect, it's like Amazon, B2B, we actually have a lot of the other businesses reaching out to us as part of their wellness aspects, right? So again, it's still a small part of our overall business. If you consider next year, we're forecasting $400 million, right? So I think the focus will still remain DTC and then retail and then B2B and marketplace. These are more like ad hoc opportunities that we'll pick up.
Alex Hantman
Sidoti
Great. Thank you very much.
Shannon Devine
Host
Thank you, Alex. That concludes our question and answer session. I'll now turn the call back over to Danny for a brief closing remarks.
Danny Young
Chief Executive Officer, Prenetics; Co-founder, IM8
Great, thank you so much everyone for tuning in today. Hopefully it was very insightful. As I mentioned, we have a very detailed shareholder letter and investor deck that we just pushed online. Again, going back to the summary wise, this quarter is another record quarter. We're heading into 2027 with a lot of strength. The revenues are growing, the cash position is growing, our cohorts are growing. Thank you everyone for tuning in and look forward to chatting with everyone in the next quarter.